Eli Lilly Financial Statements
Eli Lilly Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
© 2009 Morningstar, Inc. Financial Data provided by
Eli Lilly Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 20,378.0 | 18,633.5 | 15,691.0 |
| Gross Profit ($ mil.) | 15,995.2 | 14,384.7 | 12,144.5 |
| Operating Income ($ mil.) | (1,079.3) | 4,105.1 | 3,656.1 |
| Total Net Income ($ mil.) | (2,071.9) | 2,953.0 | 2,662.7 |
| Diluted EPS (Net Income) | (1.89) | 2.71 | 2.45 |
Eli Lilly Quarterly Statements
| Quarter Ending Jun 09 | Quarter Ending Jun 09 | Quarter Ending Mar 09 | |
|---|---|---|---|
| Revenue ($ mil.) | 5,292.8 | 5,292.8 | 5,047.0 |
| Gross Profit ($ mil.) | 4,345.4 | 4,345.4 | 4,230.6 |
| Operating Income ($ mil.) | 1,532.0 | 1,532.0 | 1,771.0 |
| Total Net Income ($ mil.) | 1,158.5 | 1,158.5 | 1,313.1 |
| Diluted EPS (Net Income) | 1.06 | 1.06 | 1.20 |
Eli Lilly Stock Quote & Chart
11/04/09 16:00:26 EST •
NYSE •
33.98
•
 0.0000
•
0.0000 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Eli Lilly Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.80 | 2.53 | 6.91 |
| Price/Earnings Ratio | (22.99) | 17.21 | 25.13 |
| Price/Book Ratio | 4.56 | 2.88 | 6.64 |
| Price/Cash Flow Ratio | 6.75 | 9.43 | 42.92 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Eli Lilly Financial Ratios
Eli Lilly Competitive Intelligence
| GlaxoSmithKline | Novo Nordisk | Pfizer | |
|---|---|---|---|
| Annual Sales ($ mil.) | 35,244.6 | 8,627.7 | 48,296.0 |
| Employees | 99,003 | 26,600 | 81,800 |
| Market Cap ($ mil.) | 116,509.9 | 39,403.1 | 114,937.9 |
Competitive Landscape
